manufacturing agreement
Charles River Laboratories to Manufacture AAV9 Vectors for Navega Therapeutics' Pain Gene Therapy
Navega was selected to be part of Charles River's cell and gene therapy accelerator program, which will provide it with manufacturing and advisory services.
Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial
The firms entered a supply and development agreement whereby Odimma will use Touchlight's doggybone DNA vector platform for its personalized immunotherapy ODI-2001.
Odimma Therapeutics, ABL Europe Partner on Personalized Cancer Vaccine Development
ABL will manufacture the viral vector component to deliver personalized cancer neoantigens as part of Odimma's ODI-2001 platform.
Chimeric Partners With WuXi Advanced Therapies to Develop and Manufacture CAR T Therapies
WuXi's manufacturing, testing, and end-to-end closed-loop processing capabilities will accelerate clinical testing of two of Chimeric's CAR T-cell therapies.
Novartis to Manufacture Carisma Therapeutics' Anti-HER2 CAR-Macrophage Therapy
Novartis has signed on as a third-party CMO to manufacture Carisma's autologous cell therapy, which is in early trials for HER2-overexpressing solid tumors.